Ganaplacide/ Lumefantrine

Novartis

Product vision
  • Uncomplicated malaria treatment for single-exposure radical cure (SERC) and/or resistance management
  • Potential for prophylaxis
MoA
  • Not yet determined. Decreased susceptibility to ganaplacide is associated with mutations in three P. falciparum genes, CARL (cyclic amine resistance locus), UDP-galactose and Acetyl-CoA transporters

Key features

Ganaplacide

  • Novel mechanism of action – activity against parasites that are resistant to current drugs

  • Rapid killing of parasites (PCT<48 hours)

  • 800mg human dose stays above Minimal Parasiticidal Concentration for >8 days

  • Transmission-blocking activity in a Standard Membrane Feeding Assay

  • Potential for prophylaxis

Lumefantrine

  • New once-daily formulation

  • Transmission-blocking activity in a Standard Membrane Feeding Assay

Status
  • Phase llb combination study ongoing

Next milestone
  • Phase llb study completion 

Previously
  • Previous names: KAF156, GNF156. Discovery partnership between MMV, Wellcome Trust, Novartis, and the Swiss Tropical and Public Health Institute

MMV Project Director
  • Dr Gonzalo Acuña